Laurus Labs is developing a third-line HIV treatment, darunavir boosted with ritonavir (DRV/r), for children. The development is under way based on an agreement inked in June 2021 by the Hyderabad-based company, Unitaid and the Clinton Health Access Initiative (CHAI).
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
